ClinicalTrialsFinder

Low PD-L1 Expressing Clinical Trials in Yantai, Shandong

1 recruitingYantai, Shandong, China

Showing 1–1 of 1 trials

Recruiting
Phase 2

Phase II Trial of Iparomlimab/Tuvonralimab (QL1706) + XELOX in HER2-Negative, Low PD-L1 G/GEJ Adenocarcinoma

HER2-negativeLow PD-L1 ExpressingUnresectable or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma
Qilu Hospital of Shandong University77 enrolled29 locationsNCT06932068